Ernexa Therapeutics Inc. Increase Decrease In Operating Lease Liability
Ernexa Therapeutics Inc. (ERNA) reported Increase Decrease In Operating Lease Liability of -$115.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-06
- Ernexa Therapeutics Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$40.00K.
- Ernexa Therapeutics Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$75.00K.
- Ernexa Therapeutics Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$63.00K.
- Ernexa Therapeutics Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$54.00K.
- Ernexa Therapeutics Inc. increase decrease in operating lease liability for fiscal 2025 was -$208.00K.
- Ernexa Therapeutics Inc. increase decrease in operating lease liability for fiscal 2024 was -$1.71M, a 227.58% decline from fiscal 2023.
- Ernexa Therapeutics Inc. increase decrease in operating lease liability for fiscal 2023 was $1.34M.
| Period end | Increase Decrease In Operating Lease Liability | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$40.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$115.00K 10-Q · filed 2026-08-06 | -$178.00K derived: sum of 3 quarters · filed 2026-08-06 | -$232.00K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | -$75.00K 10-Q · filed 2026-05-11 | -$138.00K derived: sum of 2 quarters · filed 2026-05-11 | -$192.00K derived: sum of 3 quarters · filed 2026-05-11 | -$231.00K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | -$63.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$117.00K derived: sum of 2 quarters · filed 2026-03-13 | -$156.00K derived: sum of 3 quarters · filed 2026-08-06 | -$208.00K 10-K · filed 2026-03-13 | |
| 2025-09-30 | -$54.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$93.00K derived: sum of 2 quarters · filed 2026-08-06 | -$145.00K 10-Q · filed 2025-11-07 | -$196.00K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | -$39.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$91.00K 10-Q · filed 2026-08-06 | -$142.00K derived: sum of 3 quarters · filed 2026-08-06 | -$2.79M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | -$52.00K 10-Q · filed 2026-05-11 | -$103.00K derived: sum of 2 quarters · filed 2026-05-11 | -$2.75M derived: sum of 3 quarters · filed 2026-05-11 | -$1.88M derived: sum of 4 quarters · filed 2026-05-11 | |
| 2024-12-31 | -$51.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$2.70M derived: sum of 2 quarters · filed 2026-03-13 | -$1.83M derived: sum of 3 quarters · filed 2026-03-13 | -$1.71M 10-K · filed 2026-03-13 | |
| 2024-09-30 | -$2.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$1.78M derived: sum of 2 quarters · filed 2025-11-07 | -$1.66M 10-Q · filed 2025-11-07 | -$1.11M derived: sum of 4 quarters · filed 2025-11-07 | |
| 2024-06-30 | $872.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $995.00K 10-Q · filed 2025-08-13 | $1.54M derived: sum of 3 quarters · filed 2025-08-13 | $2.55M derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $123.00K 10-Q · filed 2025-05-07 | $666.00K derived: sum of 2 quarters · filed 2025-05-07 | $1.68M derived: sum of 3 quarters · filed 2025-05-07 | ||
| 2023-12-31 | $543.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $1.55M derived: sum of 2 quarters · filed 2025-03-12 | $1.34M 10-K · filed 2025-03-12 | ||
| 2023-09-30 | $1.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $795.00K 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | -$215.00K 10-Q · filed 2024-08-13 | ||||
| 2022-12-31 | -$1.40M 10-Q · filed 2023-05-11 | ||||
| 2022-12-29 | -$1.40M 10-K · filed 2023-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |